Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Supportan returned no results
Showing 571 to 585 of 746 results for supported

  1. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  2. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

  3. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

  4. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

  5. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

  6. Urinary incontinence and pelvic organ prolapse in women: management (NG123)

    This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.

  7. Digital self-help for eating disorders: early value assessment (HTG768)

    Early value assessment (EVA) guidance on digital self-help for eating disorders.

  8. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

  9. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.

  10. Prontosan for treating acute and chronic wounds (HTG616)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

  11. Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

    Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.

  12. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.

  13. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

  14. Workplace health: management practices (NG13)

    This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.

  15. Antenatal and postnatal mental health: clinical management and service guidance (CG192)

    This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.